Bob has 32 years of healthcare venture capital investing experience including active involvement with 38 start-up or early stage companies, of which 32 achieved an IPO or successful merger. Prior to his VC activities, Bob started two companies of his own, one of which was a diagnostics lab and the other was a diagnostic product company. Bob also held an academic professorship at the University of Delaware, as well as being the Director of Technology at Becton Dickinson.
Prior to joining Latterell Venture Partners, Bob was a partner at Alliance Technology Ventures where he invested exclusively in healthcare ventures. Before ATV he was the original healthcare partner at the Sprout Group (the venture affiliate of Donaldson, Lufkin & Jenrette), and prior to Sprout he was the President of Merrill Lynch Venture Capital and Merrill Lynch R&D Management Inc. He also has served for many years as the Board Chair at the Keck Graduate Institute of Applied Life Sciences at the Claremont Colleges.
Bob holds a Ph.D. and an M.S. in chemistry from Purdue University where he was a Smith Kline Fellow, and he received his B.S. in physics from the University of Illinois at Urbana where he was a James Scholar.
Terry Cater has been an independent pharmacy and healthcare consultant and a veteran of the pharmacy industry. He has decades of experience in management of pharmacies in large, publicly traded corporations, as well as numerous startups and independent pharmacies. He was a Director of Pharmacy at Safeway and Save Mart. He was also a Vice President at both McKesson Corporation and Cardinal Health. Terry is a registered Pharmacist in the states of California, Nevada and Hawaii. He is a member of the California Pharmacists Associations and the National Community Pharmacists Association. He has served on many advisory boards. Terry has extensive experience in start-up company management.
Terry received his Bachelor of Science in Pharmacy from the University of the Pacific and his M.B.A. at Saint Mary’s College of California.
With over 38 years of experience working in the consumer package goods (CPG) industry, Frank brings considerable expertise in sales, marketing and logistics to his new position as Chief Business Officer at InterLink AI. He also brings hands-on customer knowledge and relationships across the pharma and retail markets. Previously, Frank was president of Frank Maione Consulting, where he specialized in operations and sales strategy and development, brand reinvention, new product launches, optimizing integration and business pivots. Prior to this, Frank served as president and chief customer officer Johnson and Johnson (JNJ) Consumer Sales and Logistics, USA. While here, Frank built a 500+ sales team, generating $7.5B annually via sales strategies crafted for Walmart, Target, CVS, Walgreens and Costco, among others. Frank joined JNJ with its acquisition of Pfizer Consumer Brands in 2007. At the time, Frank was vice president of sales for Pfizer, where he created a customer centric mind shift that elevated consumer sales from a sixth overall industry ranking to number one. In recognition for his efforts, Frank was honored with the President’s Innovation Award (2003) and the President’s Leadership Award (2005). He was also tasked with leading the sales integration of Pfizer into JNJ. Frank began his career at the retail rep level for Warner Lambert in 1976. He has a Bachelor’s of Science degree from California Coast University.
Ram has 15 years of experience in image processing and machine learning. He has had 8 years of experience in product development with specific emphasis on high throughput intelligent systems. Prior to working at InterLink AI, Ram has had experience in the area of life sciences and in the semiconductor industry. At Varian Semiconductors, he led many computer vision projects.
Ram holds a Ph.D. and M.S. in Mechanical Engineering and an M.S. in Biomedical Engineering from the University of Wisconsin – Madison.
Jim has years of experience with leadership in building and developing customer-oriented teams and managing programs for technical & customer support, field service, implementation, training and professional services. He has been: a Technical Support Manager at Intuitive Surgical, Inc., a Program Manager for certification and training at Varian Medical Systems, and a Director of Technical Support at Bytemobile, Inc. in Mountain View, CA. Jim has experience in both small and large companies.
Jim holds a B.S.E.E. in Electrical Engineering from the University of Massachusetts, Amherst.
Rodney S. Markin previously spent 12 years as the Chairman, President and CEO of UNMC Physicians and served as the Interim Dean of the College of Medicine at UNMC. Dr. Markin’s professional and academic research interests have focused on clinical laboratory automation, which include but are not limited to, robotics, information systems, medical utilization management and outcomes optimization.
Dr. Markin received his Bachelor’s Degree in chemistry with a minor in mathematics and physics from Nebraska Wesleyan University in 1977; his Doctor of Philosophy (Ph.D.- biochemistry) from the University of Nebraska-Lincoln in 1980; his Doctor of Medicine (M.D.) degree from the University of Nebraska Medical Center (Omaha) in 1983. Dr. Markin completed his residency in pathology and laboratory medicine at the University of Nebraska Medical Center. Dr. Markin is board certified in Anatomic and Clinical Pathology.
Dr. Markin founded LAB-InterLink, a spin-out of the University of Nebraska Medical Center that provided products for hospital-based laboratory automation systems. He served as CEO of the company and provided the early funding to grow the business.
Tom Lavin is a co-founder of New Science Ventures and its Chief Financial Officer, responsible for financial, legal and administrative matters. He serves on the Board of Directors for Achronix Semiconductor Corporation, Light Sciences Oncology, and RF Arrays, Inc. and is an observer on the boards of Vorago, Juventas Therapeutics, Therox and Directed Sensing. He formerly served on the Board of Celleration (acquired by Aliqua). Prior to NSV, he was a senior professional in finance and investment banking for over 30 years. Tom has extensive experience in private and public equity and debt transactions, mergers and acquisitions and financial restructurings in the U.S. and abroad. He was head of real estate investment banking at First Boston and Smith Barney and head of commercial mortgage lending at MetLife. Tom holds an A.B. degree in Government from Wesleyan University and an M.B.A. from Harvard Business School.
Jim brings more than 25 years of pharmaceutical research and management experience to LVP. In addition to his duties at LVP, Jim is currently chairman of Oncomed Pharmaceuticals, where he previously served as the founding CEO and helped organize the formation of the company. Jim was formerly President of Roche Bioscience in Palo Alto, CA. where he had responsibility for all bioscience research and development, ranging from genetics and genomics to clinical development of numerous new pharmaceuticals. Previously, Jim served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Jim developed Remicade, the first of the TNF inhibitor biologics, as well as ReoPro, a novel platelet blocking drug used in conjunction with angioplasty.
Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.
Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.